Ipamorelin
The "cleanest" growth hormone peptide available — designed to boost your GH without the cortisol, hunger, and prolactin side effects that older peptides cause. Here's what you need to know.
Ipamorelin is a selective growth hormone secretagogue that triggers GH release from your pituitary without the cortisol and prolactin spikes that make older GH peptides problematic. It works through the ghrelin receptor — a completely different pathway from sermorelin — and the two are often combined for synergistic effect.
Often used by: Adults seeking GH optimisation with minimal side effects, athletes wanting recovery support, people looking to improve sleep and body composition.
Dive deeper into the researchCommon side effects
- Mild tingling or water retention in hands/feet
- Temporary head rush or flushing after injection
- Increased hunger in some users (less than older GHRPs)
What does Ipamorelin do?
Ipamorelin binds the ghrelin receptor on your pituitary gland and triggers a pulse of growth hormone. What makes it special is what it doesn't do: unlike older GH peptides (GHRP-6, hexarelin), ipamorelin barely raises cortisol, doesn't spike prolactin, and causes minimal hunger stimulation.
This selectivity matters because cortisol elevation counteracts the very benefits you're seeking from GH — it promotes muscle breakdown, fat storage, and insulin resistance. By avoiding this "cortisol bleed," ipamorelin delivers a cleaner GH signal.
The most common protocol combines ipamorelin with CJC-1295 (no-DAC), which works through a completely different receptor system. Together, they produce a synergistic GH pulse significantly larger than either alone.
Who uses it?
- Longevity-focused adults — the preferred GHRP for long-term GH optimisation
- Athletes — improved recovery, sleep quality, and lean mass over time
- Body composition — reduced visceral fat with consistent training and nutrition
- Those who tried older GHRPs — switching to ipamorelin for the cleaner side effect profile
What to know before trying
Ipamorelin is a research peptide — not approved for human use anywhere. It has human pharmacology data but no therapeutic trials for any specific condition. Physician supervision with IGF-1 monitoring is recommended.
Empty stomach is critical: Food — especially carbohydrates — significantly blunts GH release by raising insulin. Inject on an empty stomach (2+ hour fast) 30–60 minutes before sleep.
Cycle it: 8–12 weeks on, 4–8 weeks off. While ipamorelin has lower tachyphylaxis risk than older GHRPs, pituitary receptor desensitisation can still occur with continuous use.
The CJC-1295 stack: CJC-1295 no-DAC (100–200 mcg) + ipamorelin (100–300 mcg) in the same syringe before sleep. They activate different intracellular signalling cascades (cAMP for GHRH, IP3/DAG for ghrelin) for synergistic effect.
Want to track if your peptide protocol is working?
eterni connects your labs, supplements, and retests — so you can see real data, not just guesswork.
Get early accessFrequently Asked Questions
Ipamorelin vs GHRP-6 — which is better?
Ipamorelin is preferred for long-term use. GHRP-6 causes significant hunger, raises cortisol and prolactin, and has higher tachyphylaxis risk. Ipamorelin was engineered to remove these off-target effects while preserving the GH pulse. For longevity and clean body composition work, ipamorelin is the better choice.
How do I take ipamorelin for best results?
Inject subcutaneously 30–60 minutes before sleep on an empty stomach (no food for 2+ hours). Combine with CJC-1295 no-DAC for synergistic effect. Cycle 8–12 weeks on, 4–8 weeks off. Track IGF-1 at weeks 8–10 to confirm your response.
What does ipamorelin do for body composition?
Via GH and IGF-1 elevation, ipamorelin promotes fat oxidation (especially visceral fat) and muscle protein synthesis. Effects become apparent over 3–6 months with adequate training and protein intake. Sleep quality improvement is usually the first noticeable benefit, appearing within 2–4 weeks.
What is the right ipamorelin dosage?
100–300 mcg per injection subcutaneously. Most protocols use 200–300 mcg before sleep. When combined with CJC-1295 no-DAC (100–200 mcg), they go in the same syringe. Consistent timing matters more than exact dose precision.
How it works in your body
Ipamorelin binds the ghrelin receptor (GHS-R1a) on pituitary somatotrophs with high affinity, triggering a pulse of GH release. Its selectivity comes from its engineered structure — it activates the GH release pathway without meaningfully engaging the ACTH/cortisol, prolactin, or appetite pathways that the ghrelin receptor can also trigger in less selective peptides.
When combined with CJC-1295 no-DAC (a GHRH analogue), both receptors on the same cells are activated simultaneously, producing a synergistic GH pulse reported to be 3–10x larger than either compound alone.
What the studies show
- Selectivity: Negligible cortisol and prolactin elevation at therapeutic doses — confirmed in human pharmacokinetic studies
- GH release: Strong, dose-dependent pulsatile GH stimulation
- Tachyphylaxis: Lower receptor desensitisation risk than GHRP-6 or hexarelin with cycling
- Sleep and body composition: Consistent anecdotal reports of improved deep sleep and gradual body recomposition
What to monitor
- IGF-1 — baseline and at 8–12 weeks. Target upper third of age-adjusted range.
- Fasting glucose — baseline and at 3 months (GH affects insulin sensitivity)
- Sleep quality — weekly subjective tracking; the earliest improvement signal
- Morning cortisol — optional baseline to confirm ipamorelin's selectivity in your case
Side effects & safety
Ipamorelin's selectivity gives it a cleaner side effect profile than older GH peptides:
- Water retention — mild fluid retention, sometimes felt as tingling in hands or feet. Typically transient.
- Injection site reactions — redness or tenderness at injection site. Common with any subcutaneous injection.
- Head rush / flushing — brief warmth or flushing after injection, resolves within minutes.
- Mild hunger — less than GHRP-6 but some users notice increased appetite. Manageable since injection is before sleep.
- Vivid dreams — related to enhanced GH pulse during deep sleep. Not harmful, often reported positively.
- At excessive doses: Joint swelling, carpal tunnel symptoms, and insulin resistance — all signs of supraphysiological IGF-1. Proper dosing and monitoring prevent this.
Who should avoid it: People with active cancer, pregnant or breastfeeding women, those with uncontrolled diabetes or pituitary tumours, and anyone on medications that affect GH or insulin.
Know what's working. Know what's not.
eterni connects your lab results, supplements, and retests — so you can see the trajectory, not just a snapshot.
Join the waitlist